Literature DB >> 21409375

Prognostic factors and survival analysis of antimitochondrial antibody-positive primary biliary cirrhosis in Chinese patients.

Dan-Tong Zhao1, Hui-Yu Liao, Yan-Min Liu, Yan Zhao, Xia Feng, Hui-Ping Yan.   

Abstract

BACKGROUND AND AIMS: Primary biliary cirrhosis (PBC) is a relatively uncommon liver disease, and information on the prognosis and survival of PBC patients in mainland China is lacking. We therefore conducted a retrospective study to investigate the prognostic factors and survival in Chinese PBC patients.
METHODS: Between October 2001 and May 2009, patients registered at Beijing You'an Hospital with abnormal liver function and serum positivity for antimitochondrial antibody (AMA) and/or AMA-M2 (n = 391) were screened. Patients diagnosed with PBC were identified, and their medical data were reviewed and analyzed for mortality predictors.
RESULTS: A total of 147 PBC patients were identified (mean age: 54 years, range: 28-81), of whom 126 (85.7%) were women. At the time of diagnosis, 119 patients (81.0%) were symptomatic, 28(19.0%) had hepatic decompensation, and no patients were asymptomatic. During a median follow-up period of 48 months (range: 2-312), 36 patients (24.5%) died or underwent liver transplantation, and 65 patients (44.2%) developed hepatic decompensation. The overall 5-year survival rate was 79%. Multivariate analysis indicated that Mayo risk score ≥6.11(P = 0.008), and serum IgG ≥ 17.20 g/l (P = 0.016) were associated with mortality.
CONCLUSIONS: Most Chinese PBC patients in this study were symptomatic at diagnosis and had significant mortality. Mayo risk score, and serum IgG were independent prognostic factors for survival.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21409375     DOI: 10.1007/s10620-011-1661-7

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  33 in total

1.  Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort.

Authors:  M I Prince; A Chetwynd; W L Craig; J V Metcalf; O F W James
Journal:  Gut       Date:  2004-06       Impact factor: 23.059

Review 2.  Prognostic models including the Child-Pugh, MELD and Mayo risk scores--where are we and where should we go?

Authors:  Erik Christensen
Journal:  J Hepatol       Date:  2004-08       Impact factor: 25.083

3.  Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis.

Authors:  Minoru Nakamura; Yuki Shimizu-Yoshida; Yasushi Takii; Atsumasa Komori; Terufumi Yokoyama; Toshihito Ueki; Manabu Daikoku; Koji Yano; Takehiro Matsumoto; Kiyoshi Migita; Hiroshi Yatsuhashi; Masahiro Ito; Naohiko Masaki; Hiroshi Adachi; Yukio Watanabe; Yoko Nakamura; Takeo Saoshiro; Takeshi Sodeyama; Michiaki Koga; Shinji Shimoda; Hiromi Ishibashi
Journal:  J Hepatol       Date:  2005-03       Impact factor: 25.083

4.  A retrospective study on clinical features and prognostic factors of biopsy-proven primary biliary cirrhosis in Chinese patients.

Authors:  Grace Lai-Hung Wong; Alex Yui Hui; Vincent Wai-Sun Wong; Francis Ka-Leung Chan; Joseph Jao-Yiu Sung; Henry Lik-Yuen Chan
Journal:  Am J Gastroenterol       Date:  2005-10       Impact factor: 10.864

5.  Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients.

Authors:  M Eric Gershwin; Carlo Selmi; Howard J Worman; Ellen B Gold; Mitchell Watnik; Jessica Utts; Keith D Lindor; Marshall M Kaplan; John M Vierling
Journal:  Hepatology       Date:  2005-11       Impact factor: 17.425

6.  Pathohistological study on liver cirrhosis in diabetes mellitus.

Authors:  T Hano
Journal:  Kobe J Med Sci       Date:  1968-06

7.  Epidemiology and natural history of primary biliary cirrhosis in a US community.

Authors:  W R Kim; K D Lindor; G R Locke; T M Therneau; H A Homburger; K P Batts; B P Yawn; J L Petz; L J Melton; E R Dickson
Journal:  Gastroenterology       Date:  2000-12       Impact factor: 22.682

8.  Differences between Caucasian, African American, and Hispanic patients with primary biliary cirrhosis in the United States.

Authors:  Marion G Peters; Adrian M Di Bisceglie; Kris V Kowdley; Nancy L Flye; Velimir A Luketic; Santiago J Munoz; Guadalupe Garcia-Tsao; Thomas D Boyer; John R Lake; Maurizio Bonacini; Burton Combes
Journal:  Hepatology       Date:  2007-09       Impact factor: 17.425

9.  Primary biliary cirrhosis in Singapore: evaluation of demography, prognostic factors and natural course in a multi-ethnic population.

Authors:  Reuben-Km Wong; Seng-Gee Lim; Aileen Wee; Yiong-Huak Chan; Myat-Oo Aung; Chun-Tao Wai
Journal:  J Gastroenterol Hepatol       Date:  2007-07-20       Impact factor: 4.029

10.  Etiologies of chronic liver diseases in Hong Kong.

Authors:  Konrad Tang-Tat Fung; James Fung; Ching-Lung Lai; Man-Fung Yuen
Journal:  Eur J Gastroenterol Hepatol       Date:  2007-08       Impact factor: 2.566

View more
  4 in total

1.  The Natural History and Prognosis of Primary Biliary Cirrhosis with Clinical Features of Autoimmune Hepatitis.

Authors:  Fan Yang; Qixia Wang; Zhaoyue Wang; Qi Miao; Xiao Xiao; Ruqi Tang; Xiaoyu Chen; Zhaolian Bian; Haiyan Zhang; Yue Yang; Li Sheng; Jingyuan Fang; Dekai Qiu; Edward L Krawitt; M Eric Gershwin; Xiong Ma
Journal:  Clin Rev Allergy Immunol       Date:  2016-02       Impact factor: 8.667

2.  Risk factors for hepatic decompensation in patients with primary biliary cirrhosis.

Authors:  Tian-Yan Shi; Li-Na Zhang; Hua Chen; Li Wang; Min Shen; Xuan Zhang; Feng-Chun Zhang
Journal:  World J Gastroenterol       Date:  2013-02-21       Impact factor: 5.742

3.  Clinical significance of IgG antimitochondrial M2 antibody levels in primary biliary cholangitis: A single center study from China.

Authors:  Lina Feng; Kaihui Dong; Xiaoxue Zhang; Bo Ma; Lin Chen; Qianqian Yang; Qingling Chen; Xiaoyu Wen; Qinglong Jin
Journal:  PLoS One       Date:  2020-11-12       Impact factor: 3.240

Review 4.  Natural history and management of primary biliary cirrhosis.

Authors:  Nadya Al-Harthy; Teru Kumagi
Journal:  Hepat Med       Date:  2012-12-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.